References
- Bi YA, Kazolias D, Duignan DB. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658–1665.
- Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22: 357–368.
- Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. (2008). In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268–275.
- Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF. (2009). Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci 108:492–500.
- Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori T, Ishizaki T. (2003). An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol 56:537–544.
- Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ. (2001). Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 14:1139–1162.
- Kamel A, Obach RS, Tseng E, Sawant A. (2010). Metabolism, pharmacokinetics and excretion of the GABAA receptor partial agonist [14C]CP-409,092 in rats. Xenobiotica (In Press).
- Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. (1999a). Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637–644.
- Liu X, LeCluyse EL, Brouwer KR, Gan L-S, Lemasters JJ, Stieger B, Meier PJ, Brouwer KL. (1999b). Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12–G21.
- Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822–2835.
- Obach RS. (2001). The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 4:36–44.
- Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58.
- Olsen RW, Tobin AJ. (1990). Molecular biology of GABAA receptors. FASEB J 4:1469–1480.
- Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751–790.
- Rudorfer MV. (1992). Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 28:45–57.
- Shugarts S, Benet LZ. (2009). The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039–2054.
- Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23.